[1]
|
Tuder, R.M., Archer, S.L., Dorfmüller, P., Erzurum, S.C., Guignabert, C., Michelakis, E., Rabinovitch, M., Schermuly, R., Stenmark, K.R. and Morrell, N.W. (2013) Relevant Issues in the Pathology and Pathobiology of Pulmonary Hyper-tension. Journal of the American College of Cardiology, 62, D4-D12. https://doi.org/10.1016/j.jacc.2013.10.025
|
[2]
|
Hoeper, M.M., Bogaard, H.J., Condliffe, R., Frantz, R., Khanna, D., Kurzyna, M., Langleben, D., Manes, A., Satoh, T. and Torres, F. (2013) Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 62, D42-D50. https://doi.org/10.1016/j.jacc.2013.10.032
|
[3]
|
Galie, N., Humbert, M., Vachiery, J.L., Gibbs, S., Lang, I., Tor-bicki, A., et al. (2015) 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Respiratory Journal, 46, 903-975.
https://doi.org/10.1183/13993003.01032-2015
|
[4]
|
Budhiraja, R., Tuder, R.M. and Hassoun, P.M. (2004) Endo-thelial Dysfunction in Pulmonary Hypertension. Circulation, 109, 159-165. https://doi.org/10.1161/01.CIR.0000102381.57477.50
|
[5]
|
Li, H. and Forstermann, U. (2000) Nitric Oxide in the Pathogenesis of Vascular Disease. The Journal of Pathology, 190, 244-254. https://doi.org/10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8
|
[6]
|
Li, H., Wallerath, T. and Forstermann, U. (2002) Physiological Mechanisms Regulating the Expression of Endothelial-Type NO Synthase. Nitric Oxide, 7, 132-147. https://doi.org/10.1016/S1089-8603(02)00127-1
|
[7]
|
Davenport, A.P., Hyndman, K.A., Dhaun, N., Southan, C., Kohan, D.E. and Pollock, J.S. (2016) Endothelin. Pharmacological Reviews, 68, 357-418. https://doi.org/10.1124/pr.115.011833
|
[8]
|
Simmet, T., Pritze, S., Thelen, K.I. and Peskar, B.A. (1992) Release of Endothelin in the Oleic Acid-Induced Respiratory Distress Syndrome in Rats. European Journal of Pharmacology, 211, 319-322.
https://doi.org/10.1016/0014-2999(92)90387-J
|
[9]
|
D’Orléans-Juste, P., Davenport, A.P., Godfraind, T., Maguire, J.J., Ohlstein, E.H. and Ruffolo, R.R. (2019) Endothelin Receptors (Version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE, 1-8. https://doi.org/10.2218/gtopdb/F21/2019.4
|
[10]
|
Enevoldsen, F.C., Sahana, J., Wehland, M., Grimm, D., Infanger, M. and Krüger, M. (2020) Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy. Journal of Clinical Medicine, 9, 824.
https://doi.org/10.3390/jcm9030824
|
[11]
|
Nicholson, S.K., Tucker, G.A. and Brameld, J.M. (2008) Effects of Die-tary Polyphenols on Gene Expression in Human Vascular Endothelial Cells. Proceedings of the Nutrition Society, 67, 42-47.
https://doi.org/10.1017/S0029665108006009
|
[12]
|
Zhao, Y., Vanhoutte, P.M. and Leung, S.W. (2015) Vascular Nitric Oxide: Beyond eNOS. Journal of Pharmacological Sciences, 129, 83-94. https://doi.org/10.1016/j.jphs.2015.09.002
|
[13]
|
Corder, R., Douthwaite, J.A., Lees, D.M., Khan, N.Q., Viseu Dos Santos, A.C., Wood, E.G. and Carrier, M.J. (2001) Endothelin-1 Synthesis Reduced by Red Wine. Nature, 414, 863-864. https://doi.org/10.1038/414863a
|
[14]
|
Thompson, A.M., Martin, K.A. and Rzucidlo, E.M. (2014) Resveratrol Induces Vascular Smooth Muscle Cell Differentiation through Stimulation of SirT1 and AMPK. PLoS ONE, 9, e85495.
https://doi.org/10.1371/journal.pone.0085495
|
[15]
|
Wang, D., Uhrin, P., Mocan, A., Waltenberger, B., Breuss, J.M., Tewari, D., Mihaly-Bison, J., Huminiecki, L., Starzynski, R.R., Tzvetkov, N.T., et al. (2018) Vascular Smooth Muscle Cell Proliferation as a Therapeutic Target. Part 1: Molecular Targets and Pathways. Biotechnology Advances, 36, 1586-1607.
https://doi.org/10.1016/j.biotechadv.2018.04.006
|
[16]
|
Rubin, L.J. (2012) Endothelin Receptor Antagonists for the Treatment of Pulmonary Artery Hypertension. Life Sciences, 91, 517-521. https://doi.org/10.1016/j.lfs.2012.07.033
|
[17]
|
Frumkin, L.R. (2012) The Pharmacological Treatment of Pulmonary Arterial Hypertension. Pharmacological Reviews, 64, 583-620. https://doi.org/10.1124/pr.111.005587
|
[18]
|
Dupuis, J., Goresky, C.A. and Fournier, A. (1996) Pulmonary Clearance of Circulating Endothelin-1 in Dogs in Vivo: Exclusive Role of ETB Receptors. Journal of Applied Physiology, 81, 1510-1515.
https://doi.org/10.1152/jappl.1996.81.4.1510
|
[19]
|
Warner, T.D., Mitchell, J.A., de Nucci, G. and Vane, J.R. (1989) Endothelin-1 and Rndothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and Rabbit. Journal of Cardiovascular Pharmacology, 13, S85-S88.
https://doi.org/10.1097/00005344-198900135-00021
|
[20]
|
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T. (1988) A Novel Potent Vasoconstrictor Peptide Pro-duced by Vascular Endothelial Cells. Nature, 332, 411-415.
https://doi.org/10.1038/332411a0
|
[21]
|
Stewart, D.J., Levy, R.D., Cernacek, P. and Langleben, D. (1991) Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease? Annals of Internal Medicine, 114, 464-469.
https://doi.org/10.7326/0003-4819-114-6-464
|
[22]
|
Cody, R.J., Haas, G.J., Binkley, P.F., Capers, Q. and Kelley, R. (1992) Plasma Endothelin Correlates with the Extent of Pulmonary Hypertension in Patients with Chronic Congestive Heart Failure. Circulation, 85, 504-509.
https://doi.org/10.1161/01.CIR.85.2.504
|
[23]
|
Boesen, E.I. (2015) Endothelin Receptors, Renal Effects and Blood Pressure. Current Opinion in Pharmacology, 21, 25-34. https://doi.org/10.1016/j.coph.2014.12.007
|
[24]
|
Wei, A., Gu, Z., Li, J., et al. (2016) Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights from the Meta-Analysis of 4894 Patients from 24 Randomized Double-Blind Placebo-Controlled Clinical Trials. Journal of the American Heart Association, 5, e003896. https://doi.org/10.1161/JAHA.116.003896
|
[25]
|
Paul, G.A., Gibbs, J.S., Boobis, A.R., Abbas, A. and Wilkins, M.R. (2005) Bosentan Decreases the Plasma Concentration of Sildenafil When Coprescribed in Pulmonary Hypertension. British Journal of Clinical Pharmacology, 60, 107- 112. https://doi.org/10.1111/j.1365-2125.2005.02383.x
|
[26]
|
McLaughlin, V., Channick, R.N., Ghofrani, H.A., et al. (2015) Bosentan Added to Sildenafil Therapy in Patients with Pulmonary Arterial Hypertension. European Respiratory Journal, 46, 405-413.
https://doi.org/10.1183/13993003.02044-2014
|